Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert M. Jotte, of the Rocky Mountain Cancer Center in Denver, Colorado.

The primary objective of this study is to compare the efficacy of the standard of care for this patient population to the standard of care in combination with AEG35156. Recruitment for this trial is expected to be completed prior to the end of 2009.

"Preliminary evidence of activity was observed in the Phase 1 portion of this study and encouraged us to amend the clinical protocol to provide for a control arm for the Phase 2 portion of the study" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

"Our clinical program around AEG35156 continues to accelerate and expand as we seek to move this therapeutic forward to more advanced stages of clinical development," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "The initiation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in AML at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to announce over the course of 2009."

About AEG35156

Ca
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...30, 2009 An international team of applied scienti...ch have demonstrated compact, multibeam, and multi...of the light spectrum (infrared). By contrast, typ...ined wavelength. The innovative multibeam lasers h...e chemical sensing pollution monitoring, optical w...
(Date:11/30/2009)..., Nov. 30 Acuo Technologies, devel... software, data migration tools and services, toda...Clinics for a new Vendor Neutral Archive (VNA), pr... Allina network of hospitals, clinics and affiliat...cuo Technologies DICOM Services Grid(TM) Software....
(Date:11/30/2009)...ov. 30 Novavax, Inc. (Na...nounced today that the company will be presenting ...December 2, 2009 at 12:30 pm local time at The New...verview of the company,s business strategy, resear...s. A link to the live audio only presentation can...
(Date:11/30/2009)...vember 30 Biopharmaceutical compan...ients have been enrolled in its,multinational regi...s,designed to show reduction in transplant related...eneic stem cell transplantation with a mismatched,...ligible for an allogeneic,stem cell transplantatio...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2
...6 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX:...ulatory agency has granted,marketing approval for ...the first Asian approval of Aridol," said Pharmaxi...a is an important base from which,to launch and gr...ion,asthma sufferers and yet only 160,000 bronchia...
...ar energy cheaper and more efficient is the aim of...lifornia, Davis, and Q1 NanoSystems. The universit...., have agreed on terms for exclusive licensing of...stemming from inventions both on and off campus. ,...facture of very thin, very small wires, films and ...
.... 16 Gen-Probe Incorporated,(Nasdaq: GPRO ) anno...th,quarter and full year 2007 financial results on... p.m. Eastern Time (ET). The announcement will be,...ed by Henry L. Nordhoff,chairman, president and ch...ice president, finance, and chief financial office...
Other Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Solar energy technology licensed 2Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call 2
(Date:11/30/2009)...scientists from The Forsyth Institute, the Univers...Wadsworth Center, have used state-of-the-art techn...reponema pallidum, the bacterium which causes syph... the bacteria can now be shown in three dimensions...en and reveals previously unknown features, which ...
(Date:11/30/2009)...ov. 30, 2009) Scientists and engineers from two o...ergy will come together Dec. 7 with leading acade... pumping blood. , Much like moving oil through a...ody. Both systems need clean, well-functioning pi...sion, to function efficiently. Both industries als...
(Date:11/30/2009)...temperatures continue to rise scientists are prese...ow species respond and adapt. In a paper published...sco Rodriguez-Trelles and Dr Miguel Rodriguez asse...rming of approximately 0.6˚C has already affe... facing ecologists and evolutionary biologists is ...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3How can scientists measure evolutionary responses to climate change? 2GreenHouse and Allard Research and Development Partner to Revolutionize Large Scale Ethanol Fuel Systems 14549 1GreenHouse and Allard Research and Development Partner to Revolutionize Large Scale Ethanol Fuel Systems 14549 2GreenHouse and Allard Research and Development Partner to Revolutionize Large Scale Ethanol Fuel Systems 14549 3New IVF Guidelines Aim to Reduce Multiple Births 59861 1New IVF Guidelines Aim to Reduce Multiple Births 59861 2Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 59859 1Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 59859 2Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 59859 3Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 59859 4Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 59859 5
...Using robotics to manipulate the brain,s perceptio...ers have deepened our understanding of the importa...ntrol of speech. The findings are reported by Sazz...appear in the October 10th issue of the journal Cu... speak, our ability to effectively produce words i...
...When nerve cells excite muscle fibers to flex, get...ht place can mean the difference between feats of ...roteins that have been shown to be major players i...g a flash-freeze physical-fixation technique that ... in neuromuscular synapses. The technique was used...
...In one of the first national studies on guidelines...e in hospitals, researchers from the Indiana Unive...e, Inc. and the Richard Roudebush Veterans Adminis...follow national guidelines on controlling antibiot... , In a study published in the October issue of In...
Other Biology News:Sensory feedback during speech: The brain attunes to more than just sound 2Fast-freeze snapshot yields new picture of nerve-muscle junction 2Controlling antibiotics and antibiotic resistance in hospitals 2
RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen
FastStart High Fidelity PCR System, dNTPack (Not available in US) from Roche Applied Science
Biolase Core Kit from Bioline
...eic acids ,The GC-RICH PCR System, a blend of T...owers through templates that are difficult or impo... blends of polymerases. The enhanced processivity ...ution combine to deliver superior performance esp...
Biology Products: